Biotech looking for collaboration partners: Cell therapy and cell-derived products

HAON Life Science is an Irish biotechnology company developing next-generation allogeneic cell therapies and cell-derived products based on proprietary placental endothelial colony-forming cell (ECFC) and mesenchymal stromal cell (MSC) platforms.

HAON combines human cell biology, scalable bioprocessing, and advanced analytics to deliver robust, clinically translatable cell products, with a strong focus on vascular repair, neuroprotection, and early-life indications. The company’s platforms are designed for manufacturing consistency, regulatory readiness, and future genomic enhancement, positioning HAON as a bridge between cutting-edge cell science and real-world clinical impact.

Beyond its lead clinical focus on neonatal brain injuries and cerebral palsy, HAON’s scalable ECFC–MSC platform is deliberately designed as a multi-purpose, human-relevant cell technology.

We are open to collaboration opportunities that can benefit from HAON's enabling technology.

Cardiovascular and vascular disease modelling:

ECFC–MSC co-cultures form stable, perfusable microvasculature suitable for studying endothelial dysfunction, inflammation, thrombosis, and repair. This enables comparative cardiovascular testing, including sex-specific and disease-state-specific vascular responses, supporting calls on cardiovascular health and mechanistic disease understanding.

New Approach Methodologies (NAMs) and comparative analysis:

The platform can be integrated into organoid and organ-on-chip systems as a standardised human vascular module, enabling side-by-side comparison of compounds, biologics, and cell-based interventions. This supports regulatory-relevant NAM development, cross-laboratory reproducibility studies, and benchmarking against existing in vitro or animal models.

Drug discovery and safety pharmacology:

HAON’s cells provide predictive human endothelial and stromal readouts (barrier function, immune–vascular interactions, paracrine signalling), allowing earlier identification of efficacy or toxicity signals and reducing late-stage attrition—directly addressing EU ambitions to improve R&I productivity.

Platform evaluation and regulatory science:

Because the cells can be manufactured at scale with controlled quality attributes, they are well suited for comparability studies, potency assay development, and reference material generation, contributing to regulatory science efforts around ATMPs, NAM qualification, and translational evidence frameworks.

Future-ready innovation:

The platform is compatible with genome and epigenome engineering, CAD-driven design–build–test workflows, and automation, making it adaptable for future applications such as programmable “sense-and-respond” cells, advanced bio-printed tissues, or precision vascular models.

Together, these capabilities position HAON not only as a cell therapy developer, but also as a provider of enabling human cell technologies that can accelerate discovery, validation, and adoption of innovative health solutions across multiple Horizon Europe Health destinations.